Repatha® (Evolocumab) Four-Year Open-Label Follow-Up Study Published In 'JAMA Cardiology'
Go back to Repatha® (Evolocumab) Four-Year Open-Label Follow-Up Study Published In 'JAMA Cardiology'| Amgen Inc (NASDAQ: AMGN) | Delayed: 358.32 +3.07 (0.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $355.25 | 52 Week High | $176.85 | |||
| Open | $354.66 | 52 Week Low | $133.64 | |||
| Day High | $359.90 | P/E | 53.96 | |||
| Day Low | $353.95 | EPS | $6.64 | |||
| Volume | 1,837,911 | |||||
